Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ApoPharma's Ferriprox Clears FDA, But Needs Cardiac Safety Study

Executive Summary

FDA's Oct. 14 accelerated approval of ApoPharma's second-line oral iron chelation therapy Ferriprox (deferiprone) includes a requirement that the sponsor conduct a post-marketing QT prolongation study, which the agency did not mention in background documents before the key advisory panel vote.
Advertisement

Related Content

Keeping It Average: Post-Marketing Requirements and Commitments For Ferriprox
ApoPharma's Ferriprox Clears ODAC Based In Part On Dosing Convenience
ApoPharma's Ferriprox Clears ODAC Based In Part On Dosing Convenience
ApoPharma's Preemptive Safety Strategy For Ferriprox Includes Centralized Pharmacy Distribution
Novartis Exjade Clears FDA As First Oral Chelating Agent

Topics

Advertisement
UsernamePublicRestriction

Register

PS053865

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel